Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00377546
Recruitment Status : Completed
First Posted : September 18, 2006
Last Update Posted : September 25, 2008
Sponsor:
Information provided by:
Innovative Medical

Brief Summary:
To compare the penetration of three different NSAIDs.

Condition or disease Intervention/treatment Phase
Vitrectomy Drug: Nepafenac Drug: Ketorolac LS, Bromfenac Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double

Resource links provided by the National Library of Medicine






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Males or females scheduled to undergo Vitrectomy surgery
  • Likely to complete all study visits and able to provide informed consent
  • Visual potential of 20/25 or better

Exclusion Criteria:

  • Known contraindications to any study medication or ingredients
  • Active ocular diseases or uncontrolled systemic disease
  • Active ocular allergies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00377546


Locations
Layout table for location information
United States, Massachusetts
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Innovative Medical
Investigators
Layout table for investigator information
Principal Investigator: Jeffrey Heier, MD Ophthalmic Consultants of Boston
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00377546    
Other Study ID Numbers: 5264
First Posted: September 18, 2006    Key Record Dates
Last Update Posted: September 25, 2008
Last Verified: September 2008
Keywords provided by Innovative Medical:
Retinal Surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Ketorolac
Nepafenac
Bromfenac
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action